Study Group: Physicians who Treat Patients with Idiopathic Thromocytopenic Pupura(?)
Council Members in this Study Group: 40
Request a survey with this Study Group
Leading Experts in this Study Group
 |
What is a GLG Leader? |
Donald Fleming, MDDivision Head of Hematology and Oncology
Davis Health System, Inc.
Donald Fleming, MD, is the Head of Hematology-Oncology at the Medical Center of Vincennes. Previously, Dr. Fleming was a Tenured Professor in the Division of Hematology-Oncology at University of Louisville. He has published over 25 manuscripts in peer-reviewed journals and remains involved in clinical...
Taral Patel, MDOncologist
Mid Ohio Oncology Hematology Inc.
Taral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer, lymphoma, and growth factor. He has been on the...
Instructor in Medicine
Dana-Farber Cancer Institute, Harvard Medical School
Eric Jacobsen, MD, is a Medical Oncologist and Hematologist in the Hematology/Oncology Department at Dana Farber Cancer Institute in Boston, Massachusetts. His clinical focus is on lymphoma and is very involved in Phase II/III clinical trials for new compounds as well as stem cell transplantation.
Kenneth Algazy, MDClinical Professor of Medicine
University of Pennsylvania School of Medicine - CC
Dr. Kenneth Algazy, MD, is a Clinical Professor of Medicine at University of Pennsylvania School of Medicine. He is also a Section Chief in the Division of Hematology and Oncology at Philadelphia VA Medical Center. Dr. Algazy is involved in clinical trials in lung cancer, and interested in demographics...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Experts(?)
We may be able to analyze EGFR mutations from periperal blood of lung cancer patients. Very frequently enough tissue fromm needle biopsies are not available for analysis. This may replace the need for new biopsies.
This oral Vascular Endothelial Growth Factor (VEGF) inhibitor appears to have activity in radioresistant differentiated thyroid carcinoma.
Patients who wish to receive Avastin for breast and lung Cancer will need to pay for it themselves.
Rising costs for care of seniors in physician offices will be made more painful by the reimbursement cuts. Will it impede care of seniors??
Due to possible tumor growth warnings will be attached to the use of erythropoietin agents.
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Physician - Division Head
- Physician - Director
- Partner
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms